Biogen will open a West Coast hub in South San Francisco after acquiring a Peninsula drugmaker. HI-Bio's operations have ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Shares of Biogen Inc. BIIB slipped 4.09% to $116.82 Tuesday, on what proved to be an all-around grim trading session for the ...

Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped ...

Biogen Inc.’s chief executive officer said that the impact from US tariffs will be limited, as three-quarters of its product ...

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...

Biotech company Biogen (NASDAQ:BIIB) reported Q1 CY2025 results , with sales up 6.1% year on year to $2.43 billion. Its ...

Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies LOS ANGELES, May 08, 2025 ...

Announcing first-quarter results, Biogen CEO Chris Viehbacher admitted that tariffs are “a new topic for us,” but said he ...

Sales of multiple sclerosis drugs such as Tecfidera fell 11% to $953 million. Sales of rare disease drugs, including ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...